Compare GSUN & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSUN | PPCB |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.6M |
| IPO Year | 2020 | 2011 |
| Metric | GSUN | PPCB |
|---|---|---|
| Price | $0.23 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 3.4M |
| Earning Date | 02-13-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.06 |
| 52 Week High | $3.31 | $6.79 |
| Indicator | GSUN | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 39.84 |
| Support Level | $0.17 | $0.15 |
| Resistance Level | $0.55 | $1.44 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 9.78 | 0.21 |
Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.